World Health Conference: A Hopeful Shift in Pandemic Response

The 78th World Health Conference, kicking off Monday, presents an opportunity for unity amid growing division. With the adoption of the pandemic agreement, this event represents a crucial moment, as noted by the World Health Organization (WHO). It emphasizes the importance of collaboration and equity in our interconnected world.

Finalized in April in Geneva and endorsed by the World Health Assembly, the WHO Pandemic Agreement highlights the age-old concept of sharing technology and discusses how intellectual property (IP) is crucial during global health emergencies like the Covid-19 crisis. The draft indicates that while IP rights are vital for developing new medical products, they shouldn’t hinder countries from taking necessary steps to protect public health. There’s also recognition of the concerns regarding how these rights affect medical product prices.

Article 11 of the agreement mentions the need for “licensing, non-exclusive, global, transparent, and in the interests of developing countries,” along with support for building capacity for technology transfer specifically related to pandemic products.

During the Covid-19 pandemic, IP rights came under scrutiny, especially when India and South Africa called for a temporary waiver on patents for related medical products, including mRNA vaccines from the West. Their petition to the World Trade Organization (WTO) faced significant pushback from wealthier nations.

Countries like the US, UK, and those in the EU argue that IP rights are essential for fostering scientific innovation and that a waiver isn’t necessary for a fair vaccine distribution. They often overlook how patents can serve as barriers, as pointed out by Dr. Aisling McMahon, noting that patent holders wield considerable control over access and pricing. For instance, the US obtained nearly all of the global supply of Remdesivir, a drug believed to aid in quicker recovery from Covid-19, highlighting the implications of such control.

In a debate at the WTO regarding travel exemptions, South Africa highlighted a case involving Pfizer and GlaxoSmithKline (GSK), where patents stifled the development of alternative vaccine versions. Despite the challenges faced, MSF managed to navigate the legal complexities, albeit two decades later.

The situations outlined above not only illuminate the barriers to equitable access but also reflect the risks of inflated drug and vaccine prices driven by major pharmaceutical companies. A statement from MSF pointed out the lack of transparency in pricing from Pfizer and GSK, leading to a scenario where governments struggle to afford essential vaccines, leaving children vulnerable to diseases like pneumonia.

The ongoing discussion about the significance of IP rights in advancing science brings in agencies like the World Intellectual Property Organization (WIPO). They argue that IP rights can offer recognition and financial benefits for inventors.

Yet, there’s scant evidence supporting this view. In fact, IP rights can stifle competition and hinder motivation for innovation. A report from the Royal Society points out how these rights can prevent scientific research in various fields. Furthermore, inventions can be patented even when they are already public knowledge, fostering an environment of secrecy.

Now, considering the question of recognition for innovators, should the benefits of innovation be exclusive to individuals or shared by society? To delve into this, two studies are worth examining. One discusses how governments assist innovators through various incentives, while another notes that government support often concentrates on certain strategically chosen sectors.

This raises an important consideration: Should innovation be credited solely to those who possess rights and promote it, or should society at large benefit from it — especially when equitable access can significantly impact lives?

The dialogue around balancing innovation with equity must rest on both market realities and ethical considerations. As member states gather next week to adopt the pandemic agreement, it’s vital they convey a powerful message — that unjust innovation practices are unacceptable and cannot stand in the way of global health.